{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for m root_relationships_relatedSubstance_refPname in Related Substance Name (approximate match)
Status:
US Approved Allergenic Extract
(1972)
Source:
BLA102192
(1972)
Source URL:
First marketed in 1921
Source:
Oil of Theobroma U.S.P.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Allergenic Extract
(1972)
Source:
BLA102192
(1972)
Source URL:
First marketed in 1921
Source:
Oil of Cinnamon U.S.P.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Previously Marketed
Source:
Cimicifuga U.S.P.
(1921)
Source URL:
First marketed in 1921
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT01686698: Phase 4 Interventional Completed Cirrhosis
(2013)
Source URL:
First approved in 2023
Source:
weight loss gummies by XIAN CHIANG COMPANY LIMITED
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT03530124: Phase 4 Interventional Completed Apnea
(2018)
Source URL:
First approved in 2021
Source:
Jointox BB by Energique, Inc.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
SINGISO (0.8g) by Sae In Dang Co., Ltd.
(2016)
Source URL:
First approved in 2015
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M021
(2023)
Source URL:
First approved in 1996
Source:
Cranberry Relief by The Garmon Corporation
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
First approved in 1987
Source:
21 CFR 341
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
CONCEPT
Status:
US Approved Rx
(2020)
Source:
NDA212728
(2020)
Source URL:
First approved in 2020
Source:
NDA212728
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Bristol-Myers Squibb developed Rimegepant, also known as BMS-927711. Rimegepant is a potent, selective, competitive and orally active calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine. Rimegepant has shown in vivo efficacy without vasoconstrictor effect; it is superior to placebo at several different doses (75 mg, 150 mg, and 300 mg) and has an excellent tolerability profile.
